Boron neutron capture therapy (BNCT): Implications of neutron beam and boron compound characteristics

Floyd Wheeler, David Nigg, Jacek Capala, Peter Watkins, Corine Vroegindeweij, Iiro Auterinen, Tiina Seppälä, Darren Bleuel

    Research output: Contribution to journalArticleScientificpeer-review

    45 Citations (Scopus)

    Abstract

    The potential efficacy of boron neutron capture therapy (BNCT) for malignant glioma is a significant function of epithermal‐neutron beam biophysical characteristics as well as boron compound biodistribution characteristics. Monte Carlo analyses were performed to evaluate the relative significance of these factors on theoretical tumor control using a standard model. The existing, well‐characterized epithermal‐neutron sources at the Brookhaven Medical Research Reactor (BMRR), the Petten High Flux Reactor (HFR), and the Finnish Research Reactor (FiR‐1) were compared. Results for a realistic accelerator design by the E. O. Lawrence Berkeley National Laboratory (LBL) are also compared. Also the characteristics of the compound p‐Boronophenylaline Fructose (BPA‐F) and a hypothetical next‐generation compound were used in a comparison of the BMRR and a hypothetical improved reactor. All components of dose induced by an external epithermal‐neutron beam fall off quite rapidly with depth in tissue. Delivery of dose to greater depths is limited by the healthy‐tissue tolerance and a reduction in the hydrogen‐recoil and incident gamma dose allow for longer irradiation and greater dose at a depth. Dose at depth can also be increased with a beam that has higher neutron energy (without too high a recoil dose) and a more forward peaked angular distribution. Of the existing facilities, the FiR‐1 beam has the better quality (lower hydrogen‐recoil and incident gamma dose) and a penetrating neutron spectrum and was found to deliver a higher value of Tumor Control Probability (TCP) than other existing beams at shallow depth. The greater forwardness and penetration of the HFR the FiR‐1 at greater depths. The hypothetical reactor and accelerator beams outperform at both shallow and greater depths. In all cases, the hypothetical compound provides a significant improvement in efficacy but it is shown that the full benefit of improved compound is not realized until the neutron beam is fully optimized.
    Original languageEnglish
    Pages (from-to)1237-1244
    Number of pages8
    JournalMedical Physics
    Volume26
    Issue number7
    DOIs
    Publication statusPublished - 1999
    MoE publication typeA1 Journal article-refereed

    Fingerprint

    Boron Compounds
    Boron Neutron Capture Therapy
    Neutrons
    Biomedical Research
    Fructose
    Glioma
    Neoplasms
    Research

    Keywords

    • BNCT neutron
    • glioma
    • treatment planning

    Cite this

    Wheeler, F., Nigg, D., Capala, J., Watkins, P., Vroegindeweij, C., Auterinen, I., ... Bleuel, D. (1999). Boron neutron capture therapy (BNCT): Implications of neutron beam and boron compound characteristics. Medical Physics, 26(7), 1237-1244. https://doi.org/10.1118/1.598618
    Wheeler, Floyd ; Nigg, David ; Capala, Jacek ; Watkins, Peter ; Vroegindeweij, Corine ; Auterinen, Iiro ; Seppälä, Tiina ; Bleuel, Darren. / Boron neutron capture therapy (BNCT) : Implications of neutron beam and boron compound characteristics. In: Medical Physics. 1999 ; Vol. 26, No. 7. pp. 1237-1244.
    @article{685b72eab36e4a2785ee1d2ee68eabf0,
    title = "Boron neutron capture therapy (BNCT): Implications of neutron beam and boron compound characteristics",
    abstract = "The potential efficacy of boron neutron capture therapy (BNCT) for malignant glioma is a significant function of epithermal‐neutron beam biophysical characteristics as well as boron compound biodistribution characteristics. Monte Carlo analyses were performed to evaluate the relative significance of these factors on theoretical tumor control using a standard model. The existing, well‐characterized epithermal‐neutron sources at the Brookhaven Medical Research Reactor (BMRR), the Petten High Flux Reactor (HFR), and the Finnish Research Reactor (FiR‐1) were compared. Results for a realistic accelerator design by the E. O. Lawrence Berkeley National Laboratory (LBL) are also compared. Also the characteristics of the compound p‐Boronophenylaline Fructose (BPA‐F) and a hypothetical next‐generation compound were used in a comparison of the BMRR and a hypothetical improved reactor. All components of dose induced by an external epithermal‐neutron beam fall off quite rapidly with depth in tissue. Delivery of dose to greater depths is limited by the healthy‐tissue tolerance and a reduction in the hydrogen‐recoil and incident gamma dose allow for longer irradiation and greater dose at a depth. Dose at depth can also be increased with a beam that has higher neutron energy (without too high a recoil dose) and a more forward peaked angular distribution. Of the existing facilities, the FiR‐1 beam has the better quality (lower hydrogen‐recoil and incident gamma dose) and a penetrating neutron spectrum and was found to deliver a higher value of Tumor Control Probability (TCP) than other existing beams at shallow depth. The greater forwardness and penetration of the HFR the FiR‐1 at greater depths. The hypothetical reactor and accelerator beams outperform at both shallow and greater depths. In all cases, the hypothetical compound provides a significant improvement in efficacy but it is shown that the full benefit of improved compound is not realized until the neutron beam is fully optimized.",
    keywords = "BNCT neutron, glioma, treatment planning",
    author = "Floyd Wheeler and David Nigg and Jacek Capala and Peter Watkins and Corine Vroegindeweij and Iiro Auterinen and Tiina Sepp{\"a}l{\"a} and Darren Bleuel",
    year = "1999",
    doi = "10.1118/1.598618",
    language = "English",
    volume = "26",
    pages = "1237--1244",
    journal = "Medical Physics",
    issn = "0094-2405",
    number = "7",

    }

    Wheeler, F, Nigg, D, Capala, J, Watkins, P, Vroegindeweij, C, Auterinen, I, Seppälä, T & Bleuel, D 1999, 'Boron neutron capture therapy (BNCT): Implications of neutron beam and boron compound characteristics', Medical Physics, vol. 26, no. 7, pp. 1237-1244. https://doi.org/10.1118/1.598618

    Boron neutron capture therapy (BNCT) : Implications of neutron beam and boron compound characteristics. / Wheeler, Floyd; Nigg, David; Capala, Jacek; Watkins, Peter; Vroegindeweij, Corine; Auterinen, Iiro; Seppälä, Tiina; Bleuel, Darren.

    In: Medical Physics, Vol. 26, No. 7, 1999, p. 1237-1244.

    Research output: Contribution to journalArticleScientificpeer-review

    TY - JOUR

    T1 - Boron neutron capture therapy (BNCT)

    T2 - Implications of neutron beam and boron compound characteristics

    AU - Wheeler, Floyd

    AU - Nigg, David

    AU - Capala, Jacek

    AU - Watkins, Peter

    AU - Vroegindeweij, Corine

    AU - Auterinen, Iiro

    AU - Seppälä, Tiina

    AU - Bleuel, Darren

    PY - 1999

    Y1 - 1999

    N2 - The potential efficacy of boron neutron capture therapy (BNCT) for malignant glioma is a significant function of epithermal‐neutron beam biophysical characteristics as well as boron compound biodistribution characteristics. Monte Carlo analyses were performed to evaluate the relative significance of these factors on theoretical tumor control using a standard model. The existing, well‐characterized epithermal‐neutron sources at the Brookhaven Medical Research Reactor (BMRR), the Petten High Flux Reactor (HFR), and the Finnish Research Reactor (FiR‐1) were compared. Results for a realistic accelerator design by the E. O. Lawrence Berkeley National Laboratory (LBL) are also compared. Also the characteristics of the compound p‐Boronophenylaline Fructose (BPA‐F) and a hypothetical next‐generation compound were used in a comparison of the BMRR and a hypothetical improved reactor. All components of dose induced by an external epithermal‐neutron beam fall off quite rapidly with depth in tissue. Delivery of dose to greater depths is limited by the healthy‐tissue tolerance and a reduction in the hydrogen‐recoil and incident gamma dose allow for longer irradiation and greater dose at a depth. Dose at depth can also be increased with a beam that has higher neutron energy (without too high a recoil dose) and a more forward peaked angular distribution. Of the existing facilities, the FiR‐1 beam has the better quality (lower hydrogen‐recoil and incident gamma dose) and a penetrating neutron spectrum and was found to deliver a higher value of Tumor Control Probability (TCP) than other existing beams at shallow depth. The greater forwardness and penetration of the HFR the FiR‐1 at greater depths. The hypothetical reactor and accelerator beams outperform at both shallow and greater depths. In all cases, the hypothetical compound provides a significant improvement in efficacy but it is shown that the full benefit of improved compound is not realized until the neutron beam is fully optimized.

    AB - The potential efficacy of boron neutron capture therapy (BNCT) for malignant glioma is a significant function of epithermal‐neutron beam biophysical characteristics as well as boron compound biodistribution characteristics. Monte Carlo analyses were performed to evaluate the relative significance of these factors on theoretical tumor control using a standard model. The existing, well‐characterized epithermal‐neutron sources at the Brookhaven Medical Research Reactor (BMRR), the Petten High Flux Reactor (HFR), and the Finnish Research Reactor (FiR‐1) were compared. Results for a realistic accelerator design by the E. O. Lawrence Berkeley National Laboratory (LBL) are also compared. Also the characteristics of the compound p‐Boronophenylaline Fructose (BPA‐F) and a hypothetical next‐generation compound were used in a comparison of the BMRR and a hypothetical improved reactor. All components of dose induced by an external epithermal‐neutron beam fall off quite rapidly with depth in tissue. Delivery of dose to greater depths is limited by the healthy‐tissue tolerance and a reduction in the hydrogen‐recoil and incident gamma dose allow for longer irradiation and greater dose at a depth. Dose at depth can also be increased with a beam that has higher neutron energy (without too high a recoil dose) and a more forward peaked angular distribution. Of the existing facilities, the FiR‐1 beam has the better quality (lower hydrogen‐recoil and incident gamma dose) and a penetrating neutron spectrum and was found to deliver a higher value of Tumor Control Probability (TCP) than other existing beams at shallow depth. The greater forwardness and penetration of the HFR the FiR‐1 at greater depths. The hypothetical reactor and accelerator beams outperform at both shallow and greater depths. In all cases, the hypothetical compound provides a significant improvement in efficacy but it is shown that the full benefit of improved compound is not realized until the neutron beam is fully optimized.

    KW - BNCT neutron

    KW - glioma

    KW - treatment planning

    U2 - 10.1118/1.598618

    DO - 10.1118/1.598618

    M3 - Article

    VL - 26

    SP - 1237

    EP - 1244

    JO - Medical Physics

    JF - Medical Physics

    SN - 0094-2405

    IS - 7

    ER -